Brief: Valneva Expects 2025 Sales To Grow To EUR 170-180 Mln
20/03/2025 06:31
March 20 (Reuters) - Valneva SE VLS.PA: VALNEVA FY REVENUE EUR 169.6 MILLION VERSUS. IBES ESTIMATE EUR 186.5 MILLION VALNEVA FY NET INCOME EUR -12.2 MILLION VALNEVA FY ADJUSTED EBITDA EUR 32.9 MILLION FURTHER DATA READOUTS, PRODUCT APPROVALS AND LABEL EXTENSIONS ANTICIPATED IN 2025 PRODUCT SALES EXPECTED TO GROW TO EUR 170-180 MILLION IN 2025 TOTAL REVENUES EXPECTED TO REACH EUR 180-190 MILLION IN 2025 TOTAL RESEARCH AND DEVELOPMENT INVESTMENTS EXPECTED BETWEEN EUR 90 - EUR 100 MILLION IN 2025 TARGETING MORE THAN 50% LOWER OPERATING CASH BURN IN 2025 Source text: ID:nGNE37wsQ9 Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency